Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells

被引：0
|
作者：
Potenza, Alessia
Balestrieri, Chiara
Albarello, Luca
Pedica, Federica
Spiga, Martina
Manfredi, Francesco
Cianciotti, Beatrice C.
De lalla, Claudia
Stasi, Lorena
Tassi, Elena
Bonfiglio, Silvia
Scotti, Giulia M.
Redegalli, Miriam
Biancolini, Donatella
Abbati, Danilo
Simeoni, Fabio
Lazarevic, Dejan
Elmore, Ugo
Fiorentini, Guido
Di Lullo, Giulia
Casorati, Giulia
Doglioni, Claudio
Tonon, Giovanni
Dellabona, Paolo
Rosati, Riccardo
Aldrighetti, Luca
Ruggiero, Eliana
Bonini, Chiara
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-902
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
902
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Treatment for liver metastases from colorectal cancer
    Littlejohns, P
    Tamber, S
    Ranson, P
    Campbell, B
    LANCET ONCOLOGY, 2005, 6 (02): : 73 - 73
  • [42] CRISPR/Cas9-mediated CD39 disruption can be combined with TCR editing in T cells to improve the adoptive T cell therapy of colorectal cancer
    Potenza, A.
    Albarello, L.
    Stasi, L.
    Manfredi, F.
    Spiga, M.
    Tassi, E.
    Cianciotti, B. C.
    Abbati, D.
    Elmore, U.
    Biondi, A.
    Aldrighetti, L.
    Ruggiero, E.
    Rosati, R.
    Bonini, C.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A33 - A33
  • [43] Expression of CD39 Identifies Activated Intratumoral CD8+T Cells in Mismatch Repair Deficient Endometrial Cancer
    Lubbers, Joyce M.
    Wazynska, Marta A.
    van Rooij, Nienke
    Kol, Arjan
    Workel, Hagma H.
    Plat, Annechien
    Paijens, Sterre T.
    Vlaming, Martijn R.
    Spierings, Diana C. J.
    Elsinga, Philip H.
    Bremer, Edwin
    Nijman, Hans W.
    de Bruyn, Marco
    CANCERS, 2022, 14 (08)
  • [44] CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
    van den Bulk, Jitske
    van der Ploeg, Manon
    Ijsselsteijn, Marieke E.
    Ruano, Dina
    van der Breggen, Ruud
    Duhen, Rebekka
    Peeters, Koen C. M. J.
    Farina-Sarasqueta, Arantza
    Verdegaal, Els M. E.
    van der Burg, Sjoerd H.
    Duhen, Thomas
    de Miranda, Noel F. C. C.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [45] CRISPR/Cas9-mediated CD39 disruption can be combined with TCR editing in T cells to improve the adoptive T cell therapy of colorectal cancer
    Potenza, Alessia
    Balestrieri, Chiara
    Albarello, Luca
    Pedica, Federica
    Stasi, Lorena
    Manfredi, Francesco
    Spiga, Martina
    Tassi, Elena
    Cianciotti, Beatrice Claudia
    Abbati, Danilo
    Elmore, Ugo
    Biondi, Andrea
    Aldrighetti, Luca
    De Lalla, Claudia
    Di Lullo, Giulia
    Dellabona, Paolo
    Ruggiero, Eliana
    Rosati, Riccardo
    Bonini, Chiara
    CANCER RESEARCH, 2022, 82 (12)
  • [46] Decrease of CD39 on Peripheral Regulatory T Cells in Liver Transplant Recipients during Acute Cellular Rejection.
    Fan, Hua
    Han, Dong-Dong
    Kou, Jian-Tao
    Li, Ping
    He, Qiang
    LIVER TRANSPLANTATION, 2014, 20 : S107 - S107
  • [47] CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis
    Gupta, Vikas
    Katiyar, Shobhita
    Singh, Ankita
    Misra, Ramnath
    Aggarwal, Amita
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [48] CD39 molecule: a negative regulator expressed on T cells in patients with lung adenocarcinoma
    Tang, Lu
    Jin, Hao
    ARCHIVES OF MEDICAL SCIENCE, 2023, 19 (05) : 1558 - 1563
  • [49] Phenotype of CD39/CD73 expressed on T cells in a mouse model of IPEX syndrome
    Liu, Yuying
    Armbrister, Shabba A.
    Okeugo, Beanna
    Daniel, Rhea C.
    Rhoads, J. Marc
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [50] Review immune response of targeting CD39 in cancer
    Yao Liu
    Zhongliang Li
    Xiaoguang Zhao
    Jing Xiao
    Jiacheng Bi
    Xian-Yang Li
    Guokai Chen
    Ligong Lu
    Biomarker Research, 11
12345